The Impact of N6-methyladenosine on RNA in Lung Cancer

Lung cancer can lead to the death of many people around the world and it is a challenge faced globally. The most common type of lung cancer is non-small cell lung cancer, and it accounts for 80% to 85%. In comparison, the proportion of patients with small cell lung cancer is relatively small, which is approximately 10% to 15%. In gene editing, m6A (N6-methyladenosine) refers to the methylation of adenosine on RNA at the 6th nitrogen atom. It is a common type of RNA modification that affects processes such as RNA stability, splicing, translation, and degradation. Regulating the m6A modification level of specific genes can play an important role in certain aspects of lung cancer RNA. m6A regulatory factors including writers, erasers and readers play crucial roles in various biological processes related to RNA metabolism and gene expression. Their functions can exert an influence on the treatment of lung cancer. This view will discuss the functions of m6A methylation modification on the stability, translation and non-coding part of RNA and the newest treatment methods act m6 modification as the therapeutic target for lung cancer.